Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 9/20 | 0.51 |
| ▸ | KDM5A | P29375 | 3/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18779827 | 1.00 | NAAA (0.51) | NAAAKDM5APHF8KDM2AKDM4C | |
| SCHEMBL22181049 | 1.00 | NAAA (0.51) | NAAAKDM5APHF8KDM2AKDM4C | |
| SCHEMBL21664445 | 0.99 | NAAA (0.49) | NAAAKDM5APHF8KDM2AKDM4C | |
| SCHEMBL9752033 | 0.88 | L3MBTL1 (0.41) | NAAAHPGDMEN1KMT2ATDP1 | |
| SCHEMBL20801484 | 0.85 | NAAA (0.40) | NAAAEPHX1ASAH1 | |
| SCHEMBL21895267 | 0.84 | NAAA (0.36) | NAAAHPGDKMT2A | |
| SCHEMBL22181082 | 0.83 | NAAA (0.37) | NAAAMEN1KMT2ATDP1 | |
| SCHEMBL37833 | 0.83 | SMN1; SMN2 (0.42) | HPGDKMT2A | |
| SCHEMBL6046844 | 0.83 | SMN1; SMN2 (0.42) | HPGDKMT2A | |
| SCHEMBL16983769 | 0.83 | SMN1; SMN2 (0.42) | HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | NAAA 1169/4885KDM5A 1150/4885PHF8 2392/4885 |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | NAAA 1219/4885KDM5A 1093/4885PHF8 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.